Trial Profile
An Open-Label, Dose-Finding and Proof of Concept Study of the PD-L1 Probody Therapeutic , CX-072, as Monotherapy and in Combination With Yervoy (Ipilimumab) or With Zelboraf (Vemurafenib) in Subjects With Advanced or Recurrent Solid Tumors or Lymphomas
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 14 Feb 2022
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Pacmilimab (Primary) ; Vemurafenib (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Anal cancer; Carcinoma; Colon cancer; Colorectal cancer; Gastric cancer; Liver cancer; Lung cancer; Lymphoma; Malignant fibrous histiocytoma; Malignant melanoma; Malignant thymoma; Merkel cell carcinoma; Oesophageal cancer; Pancreatic cancer; Renal cancer; Sarcoma; Skin cancer; Solid tumours; Squamous cell cancer; Thyroid cancer; Triple negative breast cancer
- Focus Adverse reactions; First in man; Proof of concept
- Acronyms PROCLAIM-072; PROCLAIM-CX-072; PROCLAIM-CX-072-001
- Sponsors CytomX Therapeutics
- 07 Feb 2022 Status changed from active, no longer recruiting to completed.
- 19 Nov 2021 This trial has been completed in Hungary, according to European Clinical Trials Database record.
- 15 Nov 2021 This trial has been completed in Netherlands, according to European Clinical Trials Database record.